Table 2.
Top 10 Frequently Used Medications for Parkinson’s Disease by Percentage
| Drug class/Medication | All, N=6,735 | Yes, n=3,458 | No, n=3,277 | P |
|---|---|---|---|---|
| Decarboxylase inhibitors | ||||
| Carbidopa/Levodopa Immediate Release (Sinemet) | 62.7 | 71.3 | 53.6 | <0.001 |
| Carbidopa/Levodopa Controlled Release (Sinemet CR) | 15.6 | 20.8 | 10.2 | <0.001 |
| Carbidopa/Levodopa Extended Release (Rytary or Numient) | 8.3 | 12.1 | 4.3 | <0.001 |
| MAO-B inhibitors | ||||
| Rasagiline (Azilect) | 25.7 | 25.7 | 25.7 | 0.966 |
| Selegiline [Derived] | 4.1 | 3.9 | 4.3 | 0.409 |
| Dopamine agonists | ||||
| Pramipexole (Mirapex) | 11.3 | 12.0 | 10.6 | 0.068 |
| Ropinirole [Derived] | 9.2 | 10.6 | 7.8 | <0.001 |
| Requip (Ropinirole) | 8.6 | 9.9 | 7.3 | <0.001 |
| Rotigotine Transdermal Patch (Neupro Patch) | 4.5 | 5.4 | 3.5 | <0.001 |
| Adamantanes | ||||
| Amantadine (Symmetrel) | 10.1 | 12.0 | 8.1 | <0.001 |
P value describes whether there was a significant difference between those who experienced OFF periods and those who did not.